The clinical effectiveness of insulin glargine in patients with type I diabetes in Brazil: findings and implications

Página do item simplificado
dc.creatorLays Pires Marra
dc.creatorVania Eloísa de Araújo
dc.creatorGerusa Carla Correa de Oliveira
dc.creatorLeonardo Maurício Diniz
dc.creatorAugusto Afonso Guerra Júnior
dc.creatorFrancisco de Assis Acurcio
dc.creatorBrian Godman
dc.creatorJuliana Álvares Teodoro
dc.date.accessioned2025-08-05T04:04:12Z
dc.date.accessioned2025-09-08T22:49:35Z
dc.date.available2025-08-05T04:04:12Z
dc.date.issued2017-09-29
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.2217/cer-2016-0099
dc.identifier.issn20426305
dc.identifier.urihttps://hdl.handle.net/1843/84019
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.rightsAcesso Aberto
dc.subjectMedicamentos
dc.subjectDiabetes
dc.subject.otherBrasil
dc.subject.otherPesquisa de eficácia comparativa
dc.subject.otherInsulina glargina
dc.subject.otherEstudos longitudinais
dc.subject.otherInsulina NPH
dc.subject.otherDiabetes tipo I
dc.titleThe clinical effectiveness of insulin glargine in patients with type I diabetes in Brazil: findings and implications
dc.typeArtigo de periódico
local.citation.epage527
local.citation.issue6
local.citation.spage519
local.citation.volume6
local.description.resumoAim: Published studies have challenged the cost–effectiveness of insulin glargine versus neutral protamine hagedorn (NPH) insulins in Brazil with limited evidence of increased effectiveness despite considerably higher acquisition costs. However, still a controversy. Consequently, there is a need to address this. Materials & methods: Retrospective cohort study of Type I diabetes patients receiving insulin glargine in Brazil following NPH insulin who met the criteria. Results: 580 patients were enrolled. HbA1c varied from 8.80 ± 1.98% in NPH insulin users to 8.54 ± 1.88% after insulin glargine for 6 months, which is not clinically significant. Frequency of glycemic control varied from 22.6% with NPH insulin to 26.2% with insulin glargine. No statistically significant difference was observed between controlled and still uncontrolled groups for all analyzed factors including type and frequency of insulin use and carbohydrate counting. Conclusion: Limited differences between NPH insulins and insulin analogs in routine clinical care do not justify an appreciable cost difference.
local.publisher.countryBrasil
local.publisher.departmentFAR - DEPARTAMENTO DE FARMÁCIA SOCIAL
local.publisher.initialsUFMG
local.url.externahttps://becarispublishing.com/doi/10.2217/cer-2016-0099

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
The clinical effectiveness of insulin glargine in patients with Type I diabetes in Brazil findings and implications.pdf
Tamanho:
544.14 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG